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Abstract
Background: Result publication is the key step to improve the transparency of clinical trials.
Objective: To investigate the result publication rate of Chinese trials registered in World Health Organization (WHO) primary
registries.
Method: We searched 11 WHO primary registries for Chinese trials records. The progress of each trial was analyzed. We
searched for the full texts of result publications cited in the registration records. For completed trials without citations, we
searched PubMed, Embase, Chinese Biomedical Literature Database (Chinese), China Knowledge Resource Integrated
Database, and Chinese Science and Technology Periodicals Database for result publications. The search was conducted on
July 14, 2009. We also called the investigators of completed trials to ask about results publication.
Results: We identified 1294 Chinese trials records (428 in ChiCTR,743 in clinicaltrials.gov,55 in ISRCTN, 21 in ACTRN). A total
of 443 trials had been completed. The publication rate of the Chinese trials in WHO primary registries is 35.2%(156/443).The
publication rate of Chinese trials in clinicaltrials.gov, ChiCTR, ISRCTN, and ACRTN was 36.5% (53/145), 36.3% (89/245),
26.0%(9/44), and 55.6%(5/9), respectively. The publication rate of trials sponsored by industry(23.8%) was lower than that of
sponsored by central and local government(31.7%), hospital(35.1%), and universities (40.7%). The publication rate for
randomized trials was higher than that of cohort study and case-control study (33.2% versus 16.7%, 22.2%). The publication
rate for interventional studies and observational studies was similar(33.4% versus 33.3%).
Conclusion: The publication rate of the registered Chinese trials was low, with no significant difference between ChiCTR and
clinicaltrials.gov. An effective mechanism is needed to promote publication of results for registered trials in China.
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Introduction
Trial results published in peer-reviewed journals are a major
source of scientific information for health policymakers, patients,
doctors, and researchers. However, non-publication of results and
selective outcomes reporting make the available body of evidence
incomplete and possibly biased. This can lead to duplicate
research and funding, and to harm for patients whose health care
was not informed by the best evidence [1–5]. Positive results are
usually considered more interesting (and publishable) than
negative results, and the results of many trials are under disclosure.
Therefore, published trials together provide an incomplete picture
of overall research results [6–22]. Clinical trial registration was
thus established to improve the transparency of clinical trials,
reducing selective outcome reporting.
In May 2007, the International Clinical Trials Registry
Platform of the World Health Organization (WHO ICTRP) was
established to offer an international standard for trial registration.
ICTRP made trial registration the rule, not the exception. As of
July 2009,10 WHO primary registries in Australia and New
Zealand, the United Kingdom, China, India, Germany, Japan, the
Netherlands, Iran, Sri Lanka, and Africa are approved by WHO
ICTRP. Another registry, Clinicaltrials.gov, is approved by the
International Committee of Medical Journal Editors (ICMJE)[10].
ICMJE accepts registration of trials in any of the WHO ICTRP
primary registries, and WHO ICTRP accepts registrations
approved by ICMJE [11–14]. FDAAA 801(section 801 of
FDAAA, a United States public law covering clinical trial) also
calls on the US National Institutes of Health to require that
Clinicaltrials.gov entries be augmented with trial results within 12
months of trial completion or within 30 days of FDA approval (or
clearance) of a new drug, biologic, or device (with the exception of
phase I clinical trials and complementary and alternative medicine
trials)[13,15]. Our previous study showed that Chinese trials are
registered not only in the Chinese Clinical Trial Register
(ChiCTR), but also in other WHO ICTPR primary registries or
ICMJE-approved registries[16].
Many trials are conducted in China. The State Food and Drug
Administration (SFDA) of China receives about 1,250 applications
for authorization of new trials and new drug applications each
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result publication rate in China after registration. We aimed to
assess the result publication rate in the 10 WHO registries and to
identify factors associated with publication.
Materials and Methods
Inclusion and exclusion criteria
We included trials we considered to be ‘‘sponsored by China’’—
that is,either the principal investigator, the main funder,or both were
located in China. Weexcluded trialsin which study participants were
Chinese, but the trial was not sponsored by China.In this study, a
Chinese trial could be either interventional or observational.
Data collection
We searched 11 registries for trials sponsored by China: the
Australian and New Zealand Clinical Trials Registry (ACTR), the
International Standard Randomised Controlled Trial Number
Register (ISRCTN), the Chinese Clinical Trial Registry
(ChiCTR), the Iranian Registry of Clinical Trials (IRCT), the
German Clinical Trials Register (DRKS), the Japan Primary
Registries Network, the Netherlands National Trial Register
(NTR), the Sri Lanka Clinical Trials Registry (SLCTR), the
Clinical Trials Registry – India (CTRI), the Pan African Clinical
Trial Registry (PACTR), and Clinicaltrials.gov.
All records in ChiCTR were included in our analysis, and we used
‘‘China’’ as a key word in searching the other 10 registries for
potentially eligible trials. The search was conducted on July 14, 2009.
Data extraction
We designed a program using the programming language
Python to extract information about clinical trials. The program
first automatically fetches web pages of clinical trials from
registration centers and stores them in separate HTML files.
Then it utilizes specific tags and key words in HTML files to locate
each of the registration items, and extracts them. Finally, this
program compiles the extracted data and exports it into an Excel
table for further analysis. The first search was conducted on
December 31, 2009 and included 920 trial records. To guarantee
the reliability and reproducibility of the program, we checked the
920 records manually. Our check confirmed that the program
could extract the data correctly. The rate of agreement is 100%.
The final search was conducted on July 14, 2009.
The progress status of a trial was indexed as completed,
ongoing, terminated, or suspended. To find the full text of each
completed trial, we proceeded as follows (see figure 1)
1. We looked for links to published results in the registry.
2. If there were no links to published results in the registry, we used
key words from the record to search systematically for the
published study in PubMed (English language, 1966 to July 14,
2009), Embase (English language, 1974 to July 14, 2009), CNKI
(Chinese language, 1979 to July 14, 2009), Wanfang database
(Chinese language, 1990 to July 14, 2009), and CBM (Chinese
language, 1978 to July 14, 2009). We identified a citation as the
result publication by matching registration number, the authors,
institute, interventions, participants, outcome measures, study
design, and study start date in the registration record.
3. If contact information was available in the registry, we called or
emailedtheinvestigators toask for results publicationinformation.
Two authors (Liu XM and Yin SL) devised the search strategy.
Two authors (Yin SL and Song SQ) independently searched the
databases, and shared the work of calling or emailing the authors.
Differences were resolved by discussion among all the authors.
Publication of trial result
The publication rate (the proportion of included trials with
result publications) was calculated. To examine the associations
between trial characteristics and publication rate, we calculated
Figure 1. Means of obtaining full text of completed trials.
doi:10.1371/journal.pone.0012676.g001
Result Publication
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12676the publication rate for trials at different stages, and with various
sponsor types, study designs, and intervention types. The trial
stage was categorized as completed, ongoing, terminated, or
suspended; sponsor types were industry, central or local govern-
ment body, hospital, or university; study designs were observa-
tional, interventional, randomized, and non-randomized; inter-
ventions were biological, behavioral, dietary supplement, device,
procedure, drug, gene transfer, other, and not specified.
After a trial is completed, time is needed to analyze the data and
write the paper. So we conducted a sensitivity analysis in
publication rate by excluding trials completed after July 2008
from our analysis.
We also calculated the registration number reporting rate for
the publication full texts.
Statistical analysis
Publication rates were described as proportions. Data were
analyzed by EXCEL software.
Results
Search results
Number of registered trials. We initially screened 1294
records of Chinese trials in clinicaltrials.gov. After we carefully
read the registration information, we excluded 551 records with a
recruitment location in China, but no investigators affiliated with
China administratively.
We finally included 1247 records (743 in clinicaltrials.gov, 428
in ChiCTR, 55 in ISRCTN.COM, and 21 in ACTR). No records
Chinese trials were found in the Indian, German, Japanese,
Dutch, Sri Lankan, Iranian, or Pan African registries.
Result publication. As of July 14, 2009, 35.5% (443/1247)
of the registered Chinese trials had been completed. The
publication rate of the completed trials was 35.2% (156/443).
The publication rate of the completed trials in ACTR was the
highest of the 4 registries, and similar publication rates in ChiCTR
and clinicaltrials.gov were found. As of July 14, 2008, 332 trials
were completed. The publication rate was a little higher at 39.8%
than that of the trials completed before July 14, 2009 (see Table 1).
Among the 145 completed trials in ChiCTR, we found the
published results for 40 through our systematic search. We called
the investigators of the other 105 trials. A total of 51 trial
investigators were contacted; the other 54 investigators could not
be contacted because the telephone number in the registry was
wrong, the mobile phone was off, or there was no answer. The
investigator of one trial stated that the results were published but
provided no details. We did not find the publication.
The call investigation found result publications for 13 trials. The
main reasons investigators gave for non-publication were that the
manuscript was in preparation (21 trials), that there was no
intention to publish results (7 trials), or that the manuscript had
been rejected by journals (2 trials). The investigators of 7 trials said
that although the trials were indexed as ‘‘completed,’’ these trial
were not in fact completed.
We could not get the email or telephone number of the
investigators for the completed Chinese trials in clinicaltrials.gov
because contact information is only displayed in that registry when
the study is recruiting subjects. We obtained all the full texts of the
included trials in ACTR and ISRCTN. Therefore, we did not
contact the investigators for trials in these three registries.
Factors association with the result publication
Sponsorship. The publication rate for the Chinese trials
sponsored by industry was the lowest of the four sponsor types at
23.8%, while the publication rate for Chinese trials sponsored by
universities was the highest, at 40.7% (table 2).
The publication rate for trials sponsored by industry in ChiCTR
was higher than that of trials sponsored by governments or
hospitals (table 2). However, the available sample was small (only 2
trials were sponsored by industry, with 1 published and 1
unpublished result). The publication rates for government-
sponsored trials in ChiCTR, clinicaltrials.gov, and ISRCTN were
all low (table 2).
Publication rate by trial stage. Of the 743 Chinese trials in
clinicaltrials.gov, 245 (33.0%) had been completed, 23 (3.1%) had
been terminated, 5 (0.7%) had been suspended, and 470 (63.2%)
were ongoing. The publication rate of the competed, ongoing,
suspended, and terminated trials was 36.3% (89/245), 3.6% (17/
470), 10% (1/5), and 8.7% (2/23), respectively.
Of the 145 completed trials in ChiCTR, 124 (85.5%) were
retrospectively registered (registered between trial start and result
publication), and 21 (29.8%) were prospectively registered. The
publication rate of retrospectively registered trials (29.8%) was
higher than that of prospectively registered trials (14.3%).
Publication rate by study design. The publication rate of
randomized controlled trials was higher than those of cohort and
case-control studies. The result publication rates for trials of
preventative and health services research were higher than those of
supportive care, treatment and diagnostic trials. The publication rate
of interventional and observational studies was similar (Table 3).In
Clinicaltrials.gov, publication rate of randomized controlled trials was
higher than non-randomized controlled trials, publication rate of
interventional studies was higher than observational studies; while in
ChiCTR and ACTRN, it was contrary.






Publication Publication rate (%) Publication Publication rate (%)
Yes No Yes No
ChiCTR 53 92 36.5 40 61 39.6
Clinicaltrials.gov 89 156 36.3 78 118 39.8
ISRCTN 9 35 26.0 9 17 34.6
ACTR 5 4 55.6 5 4 55.6
Total 156 287 35.2 132 200 39.8
doi:10.1371/journal.pone.0012676.t001
Result Publication
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the interventions of trials was provided in ChiCTR, so we only
analyzed the publication rates for different interventions in
clinicaltrials.gov. The publication rate for biological research was
the highest (Table 4). The number of the drug trial was the most,
but its publication rate was the lowest (Table 4).
Registration number reporting in full text of result
publications
We obtained the full text of result publications for 62.2% (97/
156) of the completed trials. Only 25.8% (25/97) of the result
publications reported registration number.
Of the 38 result publications in ChiCTR, Only 1 (a doctoral
dissertation) reported a registration number.
Of the 45 result publications in clinicaltrials.gov, 21publications
for 20 trials reported registration number. Apart from one result
publication in the Chinese-language National Medical Journal of
China, the publications that reported registration number were all
published in English-language journals outside China.
Nine publication full texts for the 9 trials in ISRCTN were
obtained. Only two publications for 2 trials reported registration
numbers. Five publications for 5 trials reported informed consent
and the name of the ethical review body.
We obtained 5 publication full texts for 5 trials in ACTR. Two
of the publications reported registration numbers.
Discussion
The publication rate of completed, registered Chinese trials was
only35.2%.Even for trials had been completed since at least one
year, the publication rate was also only 39.8%. The publication
rate of registered Chinese trials is lower than the average (46%) for
all trials registered in clinicaltrials.gov. The publication rate is
similar in clinicaltrials.gov and ChiCTR. It was also similar to the
low publication rates found in previous studies [23]. A meta-
analysis showed that the publication rates for trials in inception
cohort, regulatory cohort, abstract cohort, and manuscript cohort
varied from 60% to 93% for significant results and from 20% to
86% for non significant results [23].
In 2005 ICMJE recommended that investigators be required to
prospectively register randomized controlled trials, but only a few
Chinese journals have implemented this policy. Accordingly, we
found that only 25.8% of result publications reported a registration
number. In contrast, Mathieu et al. found recently that among
articles indexed by MEDLINE in cardiology, rheumatology, and
gastroenterology, 76.4% reported the registration number [24].
This may be because higher impact journals are more likely to
require registration number reporting. Therefore, we suggest that
all journals should require submitted papers to include a
registration number.
Factors association with non publication
The low publication rate we found indicates that the current
trial registration system does not promote publication effectively. It
does, however, provide a convenient means to identify non
publication. We found several factors associated with non
publication:
Sponsorship. Trials sponsored by industry were less likely to
have result publications than trials with other funding sources,
indicating that conflict of interest may be a factor in non
publication. This accords with the findings of Ross et al., who
report that the publication rate of trials sponsored by industry is
lower than those with non-industry support (40% versus 56%) in
clinicaltrials.gov. However, Ross et al. found that the publication
rate for trials primarily sponsored by the National Institutes of
Health (NIH) is also just 40% (30/74) [15]. In contrast, Dickersin
et al. report that the publication rate for 198 clinical trials funded
by the NIH is 93%[21]. Ramsey et al. find that just 5.9% of the
oncology trials sponsored by industry in clinicaltrials.gov published
results indexed by PubMed[25]. Liebeskind et al. report that the
publication rate of trials on efficacy of acute stroke treatments
conducted between 1955 and 1999 is at 76% (136/178)[26]. A
systematic review of 6 studies of funding sources and publication
status shows that trials funded by industry are less likely published
than other funded sources [27].
Study design. We find that the publication rate for
randomized controlled trials is higher than for case control and
cohort studies. Easterbrook et al. also find that randomized






Publication Publication rate (%) Publication Publication rate (%) Publication
Yes No Yes No Yes
Industry 1 1 50.0 14 44 24.1 0
Central and local government 2 9 18.2 14 23 37.8 9
Hospital 45 77 26.2 16 24 40.0 0
University 5 5 50.0 45 65 40.0 0
ACTRN(n=9) Total (n=443)
Publication rate (%) Publication Publication rate (%) Publication Publication rate (%)
No Yes No Yes No
4 0 1 0 100 16 51 23.8
22 29.0 4 2 66.7 25 54 31.7
7 0 0 1 0 61 113 35.1
2 0 0 1 0 50 73 40.7
doi:10.1371/journal.pone.0012676.t002
Result Publication
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observational studies [20].
Intervention type. Though drug trials are the most
numerous among those registered, their publication rate is lower
than those of biological, behavioral, other, dietary supplement,
and device procedures. This suggests that the publication bias for
drug trials is more serious than for other interventional trials in
China. A similar effect is also found in clinical trials involving
acute stroke[26].
Termination/suspension. Only about one-tenth of
terminated or suspended trials had result publications, suggesting
a high risk of non publication for these trials.
In our telephone interviews, the reasons cited by investigators
for non publication included that the manuscript had been
rejected by the journal, and a lack of time for writing. This is
consistent with previous reports. Kryzyzanowska et al. interviewed
34 authors who had not published results, and found that common
reasons for failure to publish were lack of time, funds, or other
resources [22]. Other studies show that the main reason for failure
to publish results is that investigators lack the time to submit the
full manuscript to a peer-reviewed journal [21,28–30].
Reducing non publication
The Food and Drug Administration Amendment Act of 2007
requires investigators to submit results to clinicaltrials.gov.
Investigators who do not comply can be fined as much as
$10,000 per day or have their federal research funds withheld or
recovered[31]. The law may work. The publication rate of trials
sponsored by NIH (46%) is higher in clinicaltrials.gov[15] than
that of Chinese trials (35%) registered in WHO primary registries
in our study.
A recent study concludes that three proposed remedies,
financial disclosure, reporting standards, and trial registries, failed
to control sponsorship bias[32]. The low publication rate of
Chinese trials registered in clinicaltrials.gov or ChiCTR suggests
that trial registration alone, without a requirement of result
publication, does not improve publication rate. Non publication
was still common in trials registered in clinicaltrials.gov [15,24].
Table 3. Publication rate of study type and design in clinicaltrials.gov (n, %).
Study design Clinicaltrials.gov Publication rate (%) ChiCTR Publication rate (%) ISRCTN
Publication Publication Publication
Yes No Yes No Yes
Randomized controlled trial 67 108 62.0 27 70 27.8 8
Non-randomized controlled trial 10 15 40.0 5 12 29.4 1
Cohort study 2 8 20.0 1 5 16.7 -
Case-control study 1 9 10.0 1 3 25.0 -
Study type -
Prevention 13 12 52.0 3 7 30.0 -
Health services research 1 1 50.0 - - - -
Supportive care 3 4 42.9 - - - -
Treatment 60 103 36.8 21 66 24.1 -
Diagnostic 2 6 25.0 2 3 40.0 -
Interventional or observational
Interventional 80 128 38.5 23 64 26.4 9
Observational 9 28 24.3 6 4 60.0 -
Publication rate (%) ACTRN Total Publication rate (%)
Publication Publication rate (%) Publication
No Yes No Yes No
29 3 4 42.9 105 211 33.2
2 - - - - 16 29 35.6
2 - - - 3 15 16.7
2 - 2 0 100.0 4 14 22.2
-- - - -
- - - - - 16 15 51.6
- - - - - 1 1 50.0
- - - - - 3 4 42.9
- - - - - 81 169 32.4
- - - - - 4 9 30.8
33 - 3 4 42.9 115 229 33.4
2 - 2 0 100.0 17 34 33.3
doi:10.1371/journal.pone.0012676.t003
Result Publication
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no systematic enforcement of the result posting requirement has
yet been established for WHO primary registries. Posting results in
the registry and publishing in peer reviewed journals should be
encouraged to avoid a low result publication rate.
Limitations
Our study has some limitations. First, it only investigates the
publication rate of registered trials, so the time lag between trial
and publication, as well as any selective outcome reporting bias,
remain uncertain. Second, we are unable to follow up with all of
the lead investigators on completed, unpublished trials, since no
email addresses or telephone numbers are posted for completed
Chinese trials in clinicaltrials.gov, and investigators of 54 trials in
ChiCTR could not be contacted. So the publication status and
reasons for non publication of these trials is unknown. Third,
although we use a comprehensive search strategy to find the result
publications, some publications are likely omitted. In order to
more fully understand publication status in registered Chinese
trials, further research will be need to examine the time lag
between trial and publication, and the comparative publication
rates for positive and negative results.
Conclusion
Many previous studies have examined potential sources of non
publication, abbreviated publication, selective outcomes reporting,
and time lag bias[26,29–31,32]. Just two studies[15,31] have
investigated publication rate through registration[15,32]. This is
the first study to report on the publication rate of registered
Chinese trials.
Non publication trial is a more serious problem in China than in
other countries. Mandatory result posting in a registry is needed to
promote result publication. Result publication policies should
especially focus on result publication of industry-sponsored trials,
poorly designed trials, and terminated or suspended trials.
Regular, complete, and transparent reporting is urgently needed
to ensure the integrity of Chinese science.
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